Nachrichten zur Eli Lilly & Co. Aktie

Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge

Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from previous guidance of…

Market movers: Shopify, Uber, Eli Lilly, SolarEdge, CVS Health…

…

CVS blows past estimates, hikes guidance as insurance unit continues to improve

CVS also announced a new collaboration with Eli Lilly that will make Zepbound and Foundayo accessible to eligible patients on…

WDH: Gewichtssenker florieren: US-Pharmakonzern Lilly hebt erneut Umsatzziel

(Tippfehler in der Überschrift behoben) INDIANAPOLIS (dpa-AFX) - Der US-Pharmakonzern Lilly hebt…

Gewichtssenker florieren: US-Pharmakonzern Lily hebt erneut Umsatzziel

INDIANAPOLIS (dpa-AFX) - Der US-Pharmakonzern Lilly hebt nach einem starken zweiten Quartal seine Prognose weiter…

Jim Cramers top 10 things to watch in the stock market Wednesday

AMD and SpaceX are pulling back after earnings. But Eli Lilly is jumping after crushing estimates.…

Stocks making the biggest moves premarket: SpaceX, AMD, Eli Lilly, Disney & more

These are the stocks posting the largest moves premarket.…

Novo Nordisk CEO defends economics of Wegovy pill as lower prices weigh on sales; shares fall 5%

Wall Street isnt convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly…

Eli Lilly raises annual revenue forecast as obesity, diabetes drug demand stay strong

Eli Lilly and Co raised its full-year revenue forecast on Wednesday, banking on ?sustained demand for its blockbuster GLP-1 weight-loss…

Eli Lilly shares rise on revenue beat, raised outlook

Eli Lilly and Co (NYSE:LLY) shares rose nearly 7% in early trading Wednesday after the drugmaker reported second quarter results…

Novo Nordisk shares slide after guidance disappoints investors

Novo Nordisk raised its financial outlook as it tries to catch up with rival Eli Lilly in the booming GLP-1…

Are These 5 Pharma Stocks Set to Surpass Q2 Earnings Forecasts?

Amgen, Pfizer, Eli Lilly, Merck and Novo Nordisk are set to report Q2 results this week after a strong start…

Prediction: Eli Lilly Will Be Worth $2 Trillion by 2031

And it will likely be the first company in the sector to get there.…

Jim Cramer says one popular stock is meant to be owned, not traded

Most of what Cramer says on the "Mad Money" Lightning Round is fast and directional. Occasionally, he drops a framework…

Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?

Lilly (LLY) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming…

Watch Out, Eli Lilly and Novo Nordisk: Amgens Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and Its Coming for Your Patients

Will this pharma company become a new leader in the weight loss market?…

Johnson & Johnson vs. Eli Lilly: Reliable Stability vs. Rapid Revenue Growth

Johnson & Johnsons revenue has grown modestly while Eli Lillys revenue has nearly doubled in two years, narrowing a once-wide…

Goldman Sachs sees writing on the wall for Eli Lilly stock

Eli Lilly (LLY) stock has turned into one of the best comeback trades of 2026. Shares closed at $1,196.03 on…

Eli Lilly, Dell Lead Five Stocks To Watch As Leadership Shifts

As AI-related stocks weaken, new leaders emerge.…

Novo Nordisk seeks preliminary injunction against Lilly weight-loss ads

Novo Nordisk said on Friday it is seeking a preliminary U.S. court injunction to immediately block obesity ?and diabetes drug…

Eli Lilly Will File For Retatrutide Approval—As Study Shows Average Weight Loss Of 56 Pounds

Eli Lilly will seek regulatory approval for retatrutide, a powerful weight loss drug that a new study shows helped people…

Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials

There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of…

"Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly. Heres What That Means for Both Stocks.

Novo Nordisk is also demanding that Eli Lilly pull its ads and pay damages.…

Top Research Reports for Eli Lilly, Costco & Morgan Stanley

Eli Lillys GLP-1 portfolio, pipeline progress and 2026 acquisitions are driving growth despite pricing pressure and rising competition.…

Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising

Novo asked the court to permanently stop Lilly from running the "deceptive" ads and require the drugmaker to issue corrective…

Novo Nordisk Sues GLP-1 Rival Eli Lilly For Misleading Advertising

The lawsuit, filed in federal court Tuesday, accuses Eli Lilly of using outdated data in advertising campaigns.…

Novo Nordisk sues Eli Lilly over GLP-1 drug advertising claims

Novo Nordisk (NYSE:NVO) has filed a federal lawsuit against Eli Lilly, alleging that its rival’s advertising campaigns for blockbuster GLP-1…

GLP-1 Titans Clash: Comparing Eli Lilly and Novo Nordisk

LLYs leadership in obesity drugs, expanding pipeline and stronger growth outlook set it apart as investors weigh it against NVO…

Heres Why Eli Lilly (LLY) Fell More Than Broader Market

In the latest trading session, Eli Lilly (LLY) closed at $1, marking a -2.73% move from the previous day.…

Now That Eli Lilly Trades Above $1,000, Is a Stock Split Finally on the Table?

Investors have flocked to Eli Lilly for exposure to the high-growth weight loss drug market.…

The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight Loss

Theres a good reason why investors are focused on Eli Lillys GLP-1 business, but theres more going on at the…

Wegovy Pill Just Changed the GLP-1 Market. Heres Why Eli Lilly Stock Could Still Win

Novo Nordisk is finally getting one up on its biggest rival.…

Eli Lilly to Boost Neuroscience Pipeline With AtaiBeckley Buyout

LLY agrees to acquire AtaiBeckley for $2.8B upfront to expand its neuroscience pipeline with psychedelic therapies for mental health disorders.…

Eli Lillys $3.8bn psychedelics bet is built on British science

Eli Lillys first venture into psychedelic medicine, a takeover of AtaiBeckley worth up to $3.8 billion, is above all a…

AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics, says Jefferies

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC)s acquisition by Eli Lilly for up to $3.8 billion reinforces growing interest from large pharmaceutical companies...…

AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC)s acquisition by Eli Lilly for up to $3.8 billion reinforces growing interest from large pharmaceutical companies...…

Eli Lilly: Frontalangriff auf Johnson & Johnson im Markt für Depressionstherapien

Eli Lilly diversifiziert sein Geschäftsmodell über die Abnehm- und Diabetesmedikamente hinaus mit einer aggressiven Übernahmestrategie. Die Übernahme von AtaiBeckley…

UBS strongly resets Lilly stock target

Eli Lilly (LLY) has seen a lot of bullish calls from Wall Street in July.  Guggenheim, Truist, Bank of America,…

Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal

Eli Lilly said on Thursday it would buy AtaiBeckley for ?up to $3.8 billion, entering the race to develop psychedelic…

AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer

AtaiBeckley shares soared 50% premarket on Thursday after a report that Eli Lilly was in talks to acquire the psychedelic…

AtaiBeckley to be acquired by Eli Lilly in deal valued at up to $3.8 billion

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has agreed to be acquired by Eli Lilly and Co (NYSE:LLY) in a transaction valued at…

Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts

Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a -2.48% change compared to its…

Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market?

Eyes are on the rollout of Lillys new weight loss pill.…

Heres How Much Eli Lillys Weight-Loss Drugs Are Worth to Investors

Two drugs now generate almost two-thirds of the pharmaceutical giants revenue.…

Should You Buy Eli Lilly Stock? Heres My Honest Take.

There are good reasons to invest in Lilly and to hold off.…

Stocks Look Shaky, But This Sector is Booming (Biotech)

Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market leaders.…

JPMorgan resets LLY stock target on drug demand

Eli Lilly (LLY) keeps setting records, and Wall Street’s rating of its stock keeps increasing as well.  On Tuesday, one…

Is It Too Late to Buy Eli Lilly?

The stock has soared 400% in recent years.…

Prediction: Eli Lilly Stock Will Hit This Price by the End of 2026

Eli Lillys next leg of growth may have less to do with how well its weight loss drugs work and…

Eli Lilly Stock Hits a New All-Time High: Has It Gotten Too Expensive to Buy?

Shares of Eli Lilly have risen by over 40% since the company last reported earnings.…